transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device

Författare och institution:
H. Eyjolfsdottir (-); M. Eriksdotter (-); B. Linderoth (-); G. Lind (-); B. Juliusson (-); P. Kusk (-); O. Almkvist (-); N. Andreasen (-); Kaj Blennow (Institutionen för neurovetenskap och fysiologi); D. Ferreira (-); E. Westman (-); I. Nennesmo (-); A. Karami (-); T. Darreh-Shori (-); A. Kadir (-); A. Nordberg (-); E. Sundstrom (-); L. O. Wahlund (-); A. Wall (-); M. Wiberg (-); B. Winblad (-); A. Seiger (-); L. Wahlberg (-); P. Almqvist (-)
Publicerad i:
Alzheimers Research & Therapy, 8 s. Article number: 30
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Background: Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer's disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been tested in patients with AD using encapsulated cell biodelivery of NGF (NGF-ECB) in a first-in-human study. We report our results from a third-dose cohort of patients receiving second-generation NGF-ECB implants with improved NGF secretion. Methods: Four patients with mild to moderate AD were recruited to participate in an open-label, phase Ib dose escalation study with a 6-month duration. Each patient underwent stereotactic implant surgery with four NGF-ECB implants targeted at the cholinergic basal forebrain. The NGF secretion of the second-generation implants was improved by using the Sleeping Beauty transposon gene expression technology and an improved three-dimensional internal scaffolding, resulting in production of about 10 ng NGF/device/day. Results: All patients underwent successful implant procedures without complications, and all patients completed the study, including implant removal after 6 months. Upon removal, 13 of 16 implants released NGF, 8 implants released NGF at the same rate or higher than before the implant procedure, and 3 implants failed to release detectable amounts of NGF. Of 16 adverse events, none was NGF-, or implant-related. Changes from baseline values of cholinergic markers in cerebrospinal fluid (CSF) correlated with cortical nicotinic receptor expression and Mini Mental State Examination score. Levels of neurofilament light chain (NFL) protein increased in CSF after NGF-ECB implant, while glial fibrillary acidic protein (GFAP) remained stable. Conclusions: The data derived from this patient cohort demonstrate the safety and tolerability of sustained NGF release by a second-generation NGF-ECB implant to the basal forebrain, with uneventful surgical implant and removal of NGF-ECB implants in a new dosing cohort of four patients with AD.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin
Nerve growth factor, Alzheimer's disease, Regenerative medicine, Encapsulated cell biodelivery, neurodegenerative diseases, cerebrospinal-fluid, sleeping-beauty, brain, ngf, gene, csf, therapy, protein, technology, Neurosciences & Neurology
Postens nummer:
Posten skapad:
2016-08-05 10:04
Posten ändrad:
2016-08-16 14:08

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007